Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Our "Liquid Biopsy" Microcap Just Inked Its Third Coverage Deal This Year

TrovaGene Inc. (Nasdaq: TROV) - the "Liquid Biopsy" biotech that we recommended at just about this time last year - has just announced its third major healthcare-benefits deal since the start of the New Year.

And it shows this microcap healthcare play is gaining traction as an ongoing business - something you don't often see in ventures this young.

  1. Albert Bullington | April 8, 2016

    Very good report. i will buy some of the stock.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK